Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $77.20 Consensus PT from Analysts

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has earned an average rating of “Buy” from the seventeen analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $77.20.

Several equities research analysts have recently issued reports on XENE shares. HC Wainwright increased their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Wolfe Research started coverage on shares of Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Wedbush lowered their price objective on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research report on Monday, March 16th. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Finally, Bank of America reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th.

Insider Transactions at Xenon Pharmaceuticals

In other news, insider Andrea Difabio sold 1,342 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $74,118.66. Following the completion of the sale, the insider owned 7,301 shares of the company’s stock, valued at $403,234.23. This represents a 15.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ian Mortimer sold 7,308 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $403,620.84. Following the sale, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at $1,100,347.29. This represents a 26.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 296,707 shares of company stock valued at $17,845,365 over the last quarter. Corporate insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in XENE. Cinctive Capital Management LP grew its holdings in Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after purchasing an additional 263 shares during the period. Arizona State Retirement System raised its stake in Xenon Pharmaceuticals by 1.8% in the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 334 shares during the period. State of Wyoming raised its stake in Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 350 shares during the period. Quarry LP lifted its position in shares of Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 500 shares during the last quarter. Finally, Altfest L J & Co. Inc. lifted its position in shares of Xenon Pharmaceuticals by 6.5% in the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 501 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Down 0.9%

XENE stock opened at $52.99 on Friday. The business’s 50-day moving average price is $55.91 and its two-hundred day moving average price is $48.53. The firm has a market cap of $5.12 billion, a PE ratio of -11.27 and a beta of 0.62. Xenon Pharmaceuticals has a 1-year low of $30.00 and a 1-year high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same period in the prior year, the business earned ($0.83) EPS. On average, analysts forecast that Xenon Pharmaceuticals will post -4.88 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.